Physician profile
Brendan Bauer
NPI 1245202043
$547,799.93
in general payments reported to CMS, 2019-2025
65 companies · $88K in 2025
The $88K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124K · 2020: $60K · 2021: $69K · 2022: $97K · 2023: $44K · 2024: $66K · 2025: $88K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $178K · Food and Beverage: $17K · Travel and Lodging: $2,334 · Education: $301 · Consulting Fee: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $178,345.75 |
| Food and Beverage | $16,745.27 |
| Travel and Lodging | $2,334.32 |
| Education | $300.85 |
| Consulting Fee | $102.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $221,788.87 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $111,853.51 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Genzyme Corporation | $55,258.46 | 2019-2022 | |
| Abbvie INC. | $46,023.66 | 2021-2025 | Ubrelvy, Qulipta |
| Mallinckrodt Hospital Products INC. | $33,741.46 | 2023-2025 | Acthar |
| Biohaven Pharmaceutical Holding Company LTD. | $17,205.23 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14,051.28 | 2021 | |
| Allergan, INC. | $13,725.21 | 2019-2021 | |
| Tg Therapeutics, INC. | $13,350.81 | 2023-2025 | |
| Amgen INC. | $6,289.14 | 2019-2025 | Uplizna |
| Lundbeck LLC | $2,229.51 | 2019-2025 | Vyepti, Rexulti |
| Banner Life Sciences, LLC | $982.74 | 2021-2023 | |
| Genentech USA, INC. | $957.98 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Ucb, INC. | $850.05 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $712.60 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $619.03 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $554.31 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $546.09 | 2019-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $517.97 | 2019-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $514.47 | 2019-2025 | Amyvid, Emgality, Reyvow |
| Argenx US, INC. | $505.08 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Csl Behring | $497.93 | 2021-2025 | Hizentra |
| Pfizer INC. | $483.81 | 2019-2025 | |
| Celgene Corporation | $452.03 | 2021-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $367.97 | 2019-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $364.19 | 2023-2025 | Nuedexta, Rexulti |
| Jazz Pharmaceuticals INC. | $314.83 | 2021-2024 | |
| Sk Life Science, INC. | $276.49 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $248.07 | 2022-2025 | Ingrezza, Ongentys |
| Grifols USA, LLC | $207.82 | 2022-2024 | Gamunex-C |
| Janssen Pharmaceuticals, INC | $190.51 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $181.24 | 2024 | Lumryz |
| Horizon Therapeutics Plc | $173.98 | 2022-2023 | Uplizna |
| Nevro Corp. | $152.38 | 2024 | Senza |
| Neurelis, INC. | $149.26 | 2022-2025 | Valtoco |
| Axsome Therapeutics, INC. | $143.21 | 2023-2025 | Sunosi, Symbravo |
| Azurity Pharmaceuticals, INC. | $115.24 | 2023-2025 | Horizant, Horizant |
| Mdd US Operations, LLC | $107.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2019 | |
| Acorda Therapeutics, INC | $90.21 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.07 | 2024-2025 | Hyqvia |
| Kyowa Kirin, INC. | $80.57 | 2020-2022 | |
| Livanova USA, INC. | $79.14 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Amneal Pharmaceuticals LLC | $78.30 | 2023-2024 | Rytary |
| Tanabe Pharma America, INC. | $73.00 | 2019-2024 | |
| Greenwich Biosciences, INC. | $68.38 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $40.75 | 2022-2023 | Purified Cortrophin Gel |
| Janssen Biotech, INC. | $38.80 | 2025 | |
| Vanda Pharmaceuticals INC. | $32.50 | 2025 | Ponvory |
| Abbott Laboratories | $31.55 | 2022 | |
| Upsher-Smith Laboratories LLC | $30.91 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.91 | 2021-2022 | |
| Almatica Pharma LLC | $24.16 | 2021 | |
| Merz North America, INC. | $22.94 | 2019 | |
| Merz Pharmaceuticals, LLC | $22.34 | 2024 | Xeomin |
| Springworks Therapeutics, INC. | $20.90 | 2025 | Gomekli |
| Averitas Pharma INC. | $20.74 | 2025 | Qutenza |
| E.R. Squibb & Sons, L.L.C. | $20.68 | 2020 | |
| Gilead Sciences, INC. | $20.07 | 2023 | Veklury |
| Neos Therapeutics, LP | $16.75 | 2022 | |
| Impel Pharmaceuticals LLC | $16.23 | 2025 | Trudhesa |
| Collegium Pharmaceutical, INC. | $15.48 | 2022 | |
| Assertio Therapeutics, INC. | $14.38 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $12.42 | 2021 | |
| Corium, LLC | $10.92 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brendan Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.